Upstream Bio Inc (NASDAQ:UPB) does about 430.68K shares in volume on a normal day but saw 162844 shares change hands in the recent trading day. The company now has a market cap of 1.13B USD. Its current market price is $19.40, marking an increase of 8.20% compared to the previous close of $17.93. The 52 week high reached by this stock is $29.46 whilst the lowest price level in 52 weeks is $14.97. The script in recent trading has seen the stock touch a high of $75 and a low of $75.
Upstream Bio Inc (UPB) has a 20-day trading average at $20.24 and the current price is -34.15% off the 52-week high compared with 29.59% distance from its 52-week low. The 50-day simple moving average of the closing price is $22.66. If we look at the stock’s price movements over the week, volatility stands at 15.64%, which decreases to 11.83% over 1 month. It is also key to look at other market indicators of price movement for the stock, where we see that the relative strength index (RSI) is at 46.79 to suggest the stock is neutral.
The consensus objective for the share price is $52.00, suggesting that the stock has a potential upside of 62.69% over the period. The median price target is 74.13% away from the current levels at $75.
Piper Sandler initiated its price target at $75.
The current price level is -4.15%, -14.37%, and -14.38% away from its SMA20, SMA50, and SMA200 respectively, with the UPB price moving above the 50-day SMA on current market day. Upstream Bio Inc (UPB) stock is down -1.17% over the week and 6.65% over the past month. Its price is -11.82% year-to-date.
The company’s next earnings report forecasts estimating quarterly EPS at -0.46 and -4.3 for whole year. Expected sales for next quarter are $400k, which analysts say will come at $2.14M for the current fiscal year and next year at $2.3M. In addition, estimates put the company’s current quarterly revenue at an average of $397.25k.
Its 12-month price target is $75. To reach the target analysts have set, the stock logically needs to grow 62.69 percent from here. Of course, the average price target is just what the average analysts believe a stock will be worth in the next 52 weeks, and is only one metric. There are analysts with lower targets than the average, including one bearish Wall Street research firm advocating investors to wait for the price to pull back to $75, given the recent momentum. And then, on the bullish side of things, one analyst is expecting the stock to peak at $75.
Outstanding shares total 53.60M with insiders holding 19.25% of the shares and institutional holders owning 62.74% of the company’s common stock.
